Structure

2-S-(4-Isothiocyanatobenzyl)-1,4,7-triazacyclononane-1,4,7-triacetic acid

CAS
147597-66-8
Catalog Number
ACM147597668
Category
Main Products
Molecular Weight
559.9
Molecular Formula
C20H26N4O6S·3HCl

If you have any other questions or need other size, please get a quote.

  • Product Description
  • Case Study
  • Custom Reviews
  • Custom Q&A
  • Synthetic Use
  • Related Resources

Specification

Synonyms
p-SCN-Bn-NOTA
Appearance
Solid

Synthesis of p-SCN-Bn-NOTA Modified Somatropins

Bracke, Nathalie, et al. Journal of Pharmaceutical and Biomedical Analysis, 2014, 96, 1-9.

This study described the synthesis of somatropins modified at the ε-amino group of lysine with the acylated chelator S-2-(4-isothiocyanatobenzyl)-1,4,7-triazacyclononane-1,4,7-triacetic acid (p-SCN-Bn-NOTA). p-SCN-Bn-NOTA is a well-established hexadentate BFCA that forms extremely stable complexes with Ga(III). This synthetic procedure can be used to produce target-specific radiopharmaceuticals for further investigations into treatment and visualization of somatropin-specific cancers.
Synthetic procedure of Ga labeled NOTA-somatropin
· One milligram of somatropin (=45 nmol) was dissolved in 200 µL of carbonate buffer (pH 9.0; 0.1 M) and mixed with varying volumes of 20 mM p-SCN-Bn-NOTA in the same buffer, then diluted to 350 µL. This process resulted in molar ratios of 1:1, 3:1, and 10:1 of NOTA to somatropin. The resulting mixtures were incubated for 20 hours at 20 °C in the dark, with shaking at 300 rpm. The protein fraction was then collected by loading the sample onto a PD-10 Sephadex G-25 M column that had been equilibrated with a digestion buffer consisting of 10 mM ACES and 20 mM CaCl2 at pH 7.0. Following this, the samples were freeze-dried for subsequent analytical characterization.
· To label 3:1 NOTA-somatropin with gallium, a 45 nmol lyophilized protein sample was reconstituted in 450 µL of 0.6 mM GaCl3 and 0.1 M HCl, providing a 2:1 molar excess relative to the original p-SCN-Bn-NOTA concentration. Next, 20 µL of 2 M NaOH and 40 µL of a 0.1 M ammonium acetate buffer containing 0.2 mM acetylacetone (pH 5.5) were added. The mixture was then thoroughly combined and incubated for 1 hour at 20 °C in the dark while shaking at 300 rpm.

Comparison of NOTA and PCTA Chelates in 68Ga Radiolabeled Small Peptide Imaging

Ferreira, Cara L., et al. Bioconjugate Chemistry, 2012, 23(11), 2239-2246.

This work compared the chelates p-SCN-Bn-PCTA and p-SCN-Bn-NOTA in combination with cyclo-RGDyK for 68Ga radiolabeling and small peptide imaging. The following are the similarities and differences between the two:
· Both pSCN-Bn-PCTA and p-SCN-Bn-NOTA were conjugated to cyclo-RGDyK to target the αvβ3 integrin. The resulting conjugates, PCTA-RGD and NOTA-RGD, facilitated efficient room temperature radiolabeling, producing 68Ga-radiolabeled products with high radiochemical yields (RCY) and effective specific activity. The radiolabeling process is suitable for straightforward kit-type radiopharmaceutical preparation, making it ideal for application in a radiopharmacy environment.
· While 68Ga-PCTA-RGD showed reduced stability after 4 hours in the presence of apo-transferrin compared to 68Ga-NOTA-RGD, no differences in stability were noted during the 2-hour optimal window for imaging.
· Aside from kidney uptake, the in vivo uptake and clearance of 68Ga-radiolabeled PCTA-RGD and NOTA-RGD were statistically similar; both exhibited specific uptake in tumors and cleared rapidly from background tissues such as blood and muscle.
· However, 68Ga-radiolabeled PCTA-RGD had slightly lower average kidney uptake, resulting in a better tumor-to-kidney ratio compared to 68Ga-radiolabeled NOTA-RGD, which may enhance its utility for imaging applications near the kidneys.

Please kindly note that our products are for research use only.

Alfa Chemistry

For product inquiries, please use our online system or send an email to .

Alfa Chemistry
Shopping basket
Loading...
Loading...
Download PDF documentDownload
* I hereby give my consent that I may receive marketing e-mails with information on existing and new services from this company. I know that I can opt-out from receiving such e-mails at any time or by using the link which will be provided in each marketing e-mail.